DBVT
DBV Technologies S.A.
There isn't enough reported data to score DBVT yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
DBVT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
DBVT's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
DBVT PE Valuation
DBVT has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
DBVT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect DBVT's losses to shrink, with revenue growing.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
DBVT Earnings Per Share
DBVT has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
DBVT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6M | -42% |
| Q2 2026 | $700K | -52% |
| Q1 2026 | $900K | +20% |
| Q4 2025 | $645K | +26% |
| Q3 2025 | $2.8M | +159% |
| Q2 2025 | $1.5M | +26% |
| Q1 2025 | $753K | -46% |
| Q4 2024 | $511K | -94% |
DBVT's revenue has slid since its 2023 peak: $2M last quarter, down 42% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4050% | -2814 points |
| Q2 2026 | -7229% | -4422 points |
| Q1 2026 | -5322% | -1787 points |
| Q4 2025 | -6985% | -2315 points |
| Q3 2025 | -1236% | +1593 points |
| Q2 2025 | -2806% | +109 points |
| Q1 2025 | -3535% | -1505 points |
| Q4 2024 | -4669% | -4535 points |
DBVT's operating margin was −4050% last quarter, down 2814 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over DBVT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over DBVT on profitability, with a higher operating margin.
DBVT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$53.7M | -$21.1M |
| Q2 2026 | -$53M | -$19.1M |
| Q1 2026 | -$49.5M | -$29.8M |
| Q4 2025 | -$35.5M | -$23.4M |
| Q3 2025 | -$32.6M | -$9.7M |
| Q2 2025 | -$33.9M | +$1.9M |
| Q1 2025 | -$19.7M | +$16.3M |
| Q4 2024 | -$12.1M | +$1.9M |
DBVT has burned cash in almost every quarter: −$192M over the past year, against −$98M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over DBVT on cash generation, producing positive trailing cash flow while its opponent burns cash.
DBVT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4% | +17.5M shares |
| 1 year | +235% | +317M shares |
| 3 years | +4700% | +442M shares |
DBVT has 451M diluted shares, up 235% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over DBVT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
DBVT Net Leverage
DBVT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
DBVT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.9 | Neutral |
| Stochastic | 28.1 | Neutral |
DBVT's weekly RSI is 42 (neutral) and its Stochastic is 28 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
DBVT PE vs Healthcare Sector
DBVT has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
DBVT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.3 | 11% above |
| 20 week MA | $12.5 | 8.3% below |
| 50 week MA | $16.8 | 32% below |
| 100 week MA | $12.7 | 10% below |
| 200 week MA | $13.0 | 12% below |
DBVT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
DBVT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.4 | $25.8 | -31% |
| 2021 | $25.8 | $16.9 | -34% |
| 2022 | $16.9 | $14.4 | -15% |
| 2023 | $14.4 | $9.55 | -34% |
| 2024 | $9.55 | $3.19 | -67% |
| 2025 | $3.19 | $19.2 | +501% |
| 2026 YTD | $19.2 | $11.4 | -40% |
DBVT has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.